Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Hip Health and Mobility
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Rehabilitation Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Heart

Heart

Recruiting

CAN-ACCESS

The purpose of the study is to find the best technique and tools for gaining access to left and right heart arteries using x-rays that show blood flow, in patients who are having a specific Medtronic heart valve inserted.

Status
Recruiting
Principal Investigator
Janarthanan Sathananthan
Body Locations and Systems
Heart
Area
Vancouver
Age
18 and above

HORIZON

The purpose of the study is to determine the safety and effectiveness of the drug TQJ230 to lower Lipoprotein(a) to reduce cardiovascular events in patients with a history of heart disease.

Status
Recruiting
Principal Investigator
G.B. John Mancini
Body Locations and Systems
Heart
Area
Vancouver
Age
18 - 80

PULSED AF

The purpose of the study is to provide data demonstrating the safety and effectiveness of the PulseSelect™ PFA System for the treatment of atrial fibrillation.

Status
Recruiting
Principal Investigator
Jason Andrade
Body Locations and Systems
Heart
Atrial Fibrillation
Area
Vancouver
Age
18 to 80

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

The purpose of this study is to determine if the drug empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying from cardiovascular disease.

Status
Recruiting
Principal Investigator
Christopher Fordyce
Body Locations and Systems
Heart Attack
Area
Vancouver
Age
18 and above

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

The purpose of the study is to evaluate the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure.

Status
Recruiting
Principal Investigator
Graham Wong
Body Locations and Systems
Heart Failure
Area
Vancouver
Age
18 and above

Standardized Invasive Hemodynamics for Elevated Gradients Post TAVR (DISCORDANCE)

The purpose of the study is to compare differences in blood flow and valve pressures by two different methods in patients who are having transcatheter aortic valve replacement.

Status
Recruiting
Principal Investigator
David Wood
Body Locations and Systems
Heart Disease
Area
Vancouver

Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia

The purpose of this study is to evaluate the safety of etripamil nasal spray in patients with Paroxysmal Supraventricular Tachycardia (PSVT).

Status
Recruiting
Principal Investigator
Matthew Bennett
Body Locations and Systems
Arrhythmia
Area
Vancouver
Age
18 and above

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or International Treatment (SELECT)

The purpose of this study aims to assess the efficacy and safety of selexipag in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).

Status
Recruiting
Principal Investigator
Nathan Brunner
Body Locations and Systems
Heart
Lungs
Area
Vancouver
Age
18 - 85

Creation and Implementation of a BC/Canada Registry for Familial Hypercholesterolemia

Familial hypercholesterolemia (FH) is the most frequent genetic lipoprotein disorder associated with premature coronary artery disease.  The goal of this initiative is to create a registry of subjects with FH across Canada. The registry will help clinicians and researchers to determine the burden of disease and the long-term effects of treatment. 

Status
Recruiting
Principal Investigator
Liam Brunham
Body Locations and Systems
Coronary Artery Disease
Area
Vancouver

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

Status
Recruiting
Principal Investigator
Sean Virani
Body Locations and Systems
Heart Failure
Area
Vancouver
Age
18 years and above

MANTA Vascular Closure Device Clinical Study (MANTA)

Research study which tests the safety and effectiveness of a new vascular closure device to close the femoral access puncture that is created in patients who require this form of access in order to perform the planned procedure. The MANTA device is expected to seal the femoral access puncture in less than 1 minute. This may result in less blood loss and a shorter time to walking compared to alternative closure means. Use of the MANTA device in this study is experimental. All other parts of the procedure involve standard medical care

Status
Recruiting
Principal Investigator
David Wood
Body Locations and Systems
Heart
Area
Vancouver
Age
21 years and above

BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY (BLADE)

The main objective of this study is to assess the safety, efficacy and dose response of LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent in reducing restenosis as measured by Optical Coherence Tomography (OCT) at 9 months post procedure in patients with diabetes mellitus (DM).

Administration of LABR-312 at the time of PCI will reduce restenosis compared with placebo as assessed by the OCT endpoint of % neointimal hyperplasia (%NIH) volume at 9 months in patients with DM.

Status
Recruiting
Principal Investigator
David Wood
Body Locations and Systems
Diabetic Heart Disease
Area
Vancouver
Age
18 and above

PULSE (Partners Using Linked Strategies Effectively) Study

Health behaviors like physical activity and nutritious eating habits significantly reduce initial stroke risk and help prevent strokes from reoccurring. Yet, most individuals struggle to meet physical activity and nutrition recommendations. Health and health behaviors are typically linked in couples, and spouses occupy a unique position to facilitate each other’s physical activity and healthy nutrition, thereby reducing stroke risk for everyone involved. 

Status
Recruiting
Principal Investigator
Christiane Hoppmann
Body Locations and Systems
Stroke
Area
Vancouver

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA)

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.

Status
Recruiting
Principal Investigator
Sean Virani
Body Locations and Systems
Heart Failure
Area
Vancouver
Age
18 and above

Women's Heart Attack Research Program- Imaging Study (HARP)

The Women's HARP study is a multi-center, diagnostic observational study employing standardized imaging protocols in women with MINOCA (MI with Non Obstructive Coronary Arteries) to determine the underlying diagnosis in each participant. Participants will be followed for recurrent clinical events, every 6 months, for a maximum of 3 years.

Status
Recruiting
Principal Investigator
Tara Sedlak
Body Locations and Systems
Heart Attack
Heart Disease in Women
Area
Vancouver
Age
21-99

AMPLATZER™ LAA Occluder Post Approval Study (PAS)

The AMPLATZER LAA Occluder is a transcatheter, self-expanding nitinol device intended for use in preventing thrombus embolization from the LAA. The purpose of this study is to compile real world outcome data on the use of AMPLATZER LAA Occluder in subjects with non-valvular atrial fibrillation (NVAF)

Status
Recruiting
Principal Investigator
Jacqueline Saw
Body Locations and Systems
Atrial Fibrillation
Stroke
Area
Vancouver
Age
18 and above

Putting Heart Failure Patient's Experiences at the Centre of Home Health Monitoring Design

We hope to understand a heart failure patient's journey during the transition of care from the emergency department or hospital to home. We also want to explore how technology, like home health monitoring, can better support patients' recovery during this time.

Recruitment Poster

Status
Recruiting
Principal Investigator
Chad Kim Sing
Body Locations and Systems
Heart Failure
Area
Vancouver
Age
all ages

Early Aggressive Invasive Intervention for Atrial Fibrillation (EARLY-AF)

The EARLY-AF study is centered on an evaluation of the impact of the early invasive management of Atrial Fibrillation. The primary goal of the study is to evaluate the clinical effectiveness of an early invasive approach. Specifically, the investigators are aiming to evaluate if PVI performed with the Arctic Front cryoballoon is superior to AAD as first-line therapy in preventing atrial arrhythmia recurrences (arrhythmia related symptoms, hospitalisations, and health care utilization).

Status
Recruiting
Principal Investigator
Jason Andrade
Body Locations and Systems
Atrial Fibrillation
Area
Vancouver
Age
18-75

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)

INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.

Status
Recruiting
Principal Investigator
Kenneth Gin
Body Locations and Systems
Heart Failure
Heart Attack
Area
Vancouver
Age
18 and above

Canadian-Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK)

Patients on the waiting list for kidney transplantation are at risk for coronary artery disease (CAD).  The optimal strategy to monitor and maintain the cardiac fitness of these patients is unknown. Currently patients without any symptoms of CAD undergo annual testing to determine if they have disease. This study will determine if screening is necessary.

Status
Recruiting
Principal Investigator
Jagbir Gill
Body Locations and Systems
Kidney Transplantation
Coronary Artery Disease
Area
Vancouver
Age
18 and above

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page
Subscribe to Heart

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy